- Home
- ANGX vs AQST Comparison
ANGX vs AQST Comparison
Compare ANGX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | AQST |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.3M | 707.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ANGX | AQST |
|---|---|---|
| Price | $3.96 | $3.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $10.67 | $8.83 |
| AVG Volume (30 Days) | 647.9K | ★ 6.4M |
| Earning Date | 11-13-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $242,655,179.00 | $43,397,000.00 |
| Revenue This Year | $218.07 | N/A |
| Revenue Next Year | $35.82 | $43.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 110.21 | N/A |
| 52 Week Low | $3.77 | $2.12 |
| 52 Week High | $60.00 | $7.55 |
Technical Indicators
Market Signals| Indicator | ANGX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 25.88 |
| Support Level | $4.05 | $3.17 |
| Resistance Level | $4.69 | $3.55 |
| Average True Range (ATR) | 0.25 | 0.27 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 2.63 | 2.94 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.